The U.S. FDA allowed the expanded use of Sarepta's gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.
The FDA first stopped the company from marketing its products in 2022, but they have stayed on shelves pending an appeal.
Europe's aviation regulator's head would stop approving Boeing's jet production indirectly if needed but feels reassured by its response to the safety crisis.